PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation
Nihar Desai(University Health Network), Arjun Law(University of Toronto), Rajat Kumar(University Health Network), Armin Gerbitz(University Health Network), Mats Remberger(Uppsala University), Igor Novitzky‐Basso(University Health Network), Eshrak Al‐Shaibani(University Health Network), Tommy Alfaro Moya(University of Toronto), Majed Altareb(University of Toronto), Ivan Pašić(University Health Network), Auro Viswabandya(Princess Margaret Cancer Centre), Fotios V. Michelis(Princess Margaret Cancer Centre), Jonas Mattsson(University Health Network), Dennis Dong Hwan Kim(University Health Network), Jeffrey H. Lipton(Princess Margaret Cancer Centre), Wilson Lam(Princess Margaret Cancer Centre), Carol Chen(University Health Network)
Cited by 29
Related Papers
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2010|1k
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
|Leukemia|2008|354
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
|Oncotarget|2017|187
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies
|Biology of Blood and Marrow Transplantation|2018|92